Shopping Cart
- Remove All
- Your shopping cart is currently empty
Abemaciclib metabolite M18 (LSN3106729) is a potent cyclin-dependent kinase (CDK) inhibitor with antitumor properties. It has been incorporated alongside a cereblon (CRBN) ligand to develop a proteolysis-targeting chimera (PROTAC) that selectively degrades CDK4/6 [1] [2].
Pack Size | Price | Availability | Quantity |
---|---|---|---|
5 mg | Inquiry | Backorder | |
50 mg | Inquiry | Backorder |
Description | Abemaciclib metabolite M18 (LSN3106729) is a potent cyclin-dependent kinase (CDK) inhibitor with antitumor properties. It has been incorporated alongside a cereblon (CRBN) ligand to develop a proteolysis-targeting chimera (PROTAC) that selectively degrades CDK4/6 [1] [2]. |
In vitro | Abemaciclib metabolite M18 hydrochloride demonstrates a plasma half-life (T 1/2) of 43.1 hours in healthy subjects [3]. While the primary function of CDK4/6 inhibitors is to prevent retinoblastoma (RB) protein phosphorylation, leading to cell cycle arrest, they also modify cancer cell biology through additional mechanisms [4]. |
In vivo | CDK4/6 inhibitors enhance T-cell persistence and boost immunological memory in mice administered with tumor-specific CD8+ T cells [5]. |
Alias | LSN3106729 |
Molecular Weight | 494.54 |
Formula | C25H28F2N8O |
Cas No. | 2704316-81-2 |
Storage | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.